Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vicky Makker

Showing results (51-60 of 140) with videos related to

Pageof 14
Sort By:
The Journal of Pathology|November 28, 2023
Decreased HER2 expression in endometrial cancer following anti-HER2 therapyM Herman Chui, David N Brown, Arnaud Da Cruz Paula, et al.
Gynecologic Oncology|June 2, 2023
Laparoscopy with or without robotic assistance does not negatively impact long-term oncologic outcomes in patients with uterine serous carcinomaTiffany Y Sia, Derman Basaran, Christian Dagher, et al.
Gynecologic Oncology|January 23, 2024
A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)Melissa Lumish, M Herman Chui, Qin Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2018
Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid TumorsDavid M Hyman, Naiyer Rizvi, Ronald Natale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2023
A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety UpdateVicky Makker, Carol Aghajanian, Allen L Cohn, et al.
Gynecologic Oncology|September 25, 2023
Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancerWilliam A Zammarrelli, Weining Ma, Kevin Espino, et al.
Cancer Immunology, Immunotherapy : CII|July 2, 2022
Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combinationRyan M Kahn, Govind Ragupathi, Qin C Zhou, et al.
Gynecologic Oncology|October 6, 2018
Patterns of FIRST recurrence of stage IIIC1 endometrial cancer with no PARAAORTIC nodal assessmentAlessia Aloisi, João Miguel Casanova, Jill H Tseng, et al.
Gynecologic Oncology|September 7, 2024
Impact of adjuvant therapy on oncologic outcomes in uterine-confined clear cell carcinoma of the endometriumEric Rios-Doria, Silvana Pedra Nobre, Dib Sassine, et al.
Expert Review of Anticancer Therapy|March 9, 2022
Lenvatinib dose, efficacy, and safety in the treatment of multiple malignanciesRobert J Motzer, Matthew H Taylor, Thomas R Jeffry Evans, et al.
Pageof 14

Showing results (51-60 of 140) with videos related to

Sort By:
Pageof 14
The Journal of Pathology|November 28, 2023
Decreased HER2 expression in endometrial cancer following anti-HER2 therapyM Herman Chui, David N Brown, Arnaud Da Cruz Paula, et al.
Gynecologic Oncology|June 2, 2023
Laparoscopy with or without robotic assistance does not negatively impact long-term oncologic outcomes in patients with uterine serous carcinomaTiffany Y Sia, Derman Basaran, Christian Dagher, et al.
Gynecologic Oncology|January 23, 2024
A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)Melissa Lumish, M Herman Chui, Qin Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2018
Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid TumorsDavid M Hyman, Naiyer Rizvi, Ronald Natale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2023
A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety UpdateVicky Makker, Carol Aghajanian, Allen L Cohn, et al.
Gynecologic Oncology|September 25, 2023
Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancerWilliam A Zammarrelli, Weining Ma, Kevin Espino, et al.
Cancer Immunology, Immunotherapy : CII|July 2, 2022
Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combinationRyan M Kahn, Govind Ragupathi, Qin C Zhou, et al.
Gynecologic Oncology|October 6, 2018
Patterns of FIRST recurrence of stage IIIC1 endometrial cancer with no PARAAORTIC nodal assessmentAlessia Aloisi, João Miguel Casanova, Jill H Tseng, et al.
Gynecologic Oncology|September 7, 2024
Impact of adjuvant therapy on oncologic outcomes in uterine-confined clear cell carcinoma of the endometriumEric Rios-Doria, Silvana Pedra Nobre, Dib Sassine, et al.
Expert Review of Anticancer Therapy|March 9, 2022
Lenvatinib dose, efficacy, and safety in the treatment of multiple malignanciesRobert J Motzer, Matthew H Taylor, Thomas R Jeffry Evans, et al.
Pageof 14